ProMIS Neurosciences Inc.
ProMIS Neurosciences develops antibody therapies for people with neurodegenerative diseases and other diseases associated with misfolded proteins. Based in Toronto, Ontario, Canada, ProMIS uses its licensed EpiSelect computational platform to identify targets on toxic, misfolded proteins and generate antibody candidates designed to avoid their healthy counterparts. Its lead program, PMN310, is a monoclonal antibody in the Phase 1b PRECISE-AD trial for early Alzheimer’s disease. ProMIS also develops PMN267, an antibody targeting misfolded TDP-43 associated with amyotrophic lateral sclerosis and frontotemporal lobar degeneration, and a candidate antibody targeting misfolded alpha-synuclein for synucleinopathies.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ProMIS Neurosciences (PMN) reported Q3 earnings, highlighting progress in its PMN310 Alzheimer's trial. The company expects cash to last through 2027 and anticipates 12-month trial results in Q1 2027. Interim safety data was encouraging, but efficacy remains unproven. Management also announced new leadership and pipeline expansions.
ProMIS Neurosciences reported Q3 GAAP EPS of -$0.89, exceeding estimates by $0.39. The company had $44.1M in cash as of September 30, 2026, up from $6.1M at the end of 2025, due to a $70.1M private placement. Shares rose 1.72% after hours.
ProMIS Neurosciences reported Q3 2026 financials, with $44.1M cash on hand. Their PRECISE-AD Phase 1b trial for Alzheimer's is on track for 12-month topline data in Q1 2027. PMN310 showed promising interim safety and biomarker results, targeting toxic amyloid-beta oligomers. The company appointed Ivana Rubino as Chief Commercial Officer and expects funds to last through 2027.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning PMN (ProMIS Neurosciences Inc.). Coverage has skewed bullish: 1 bullish, 3 neutral, and 0 bearish.
Recent PMN coverage spans earnings, insider activity and financial news.
In the last 30 days, PMN insiders filed 3 SEC Form 4 transactions — 3 purchases ($135K) and no sales. The most active reporter was Williams Eugene with 2 filings.
Interim data are encouraging but still blinded; investors may view the safety profile positively while awaiting efficacy readout in 2027.
ProMIS Neurosciences reported Q3 GAAP EPS of -$0.89, exceeding estimates by $0.39. The company had $44.1M in cash as of September 30, 2026, up from $6.1M at the end of 2025, due to a $70.1M private placement. Shares rose 1.72% after hours.
The cash runway and upcoming topline data may reduce financing risk and could support a modest price gain.
Positive interim safety data and sufficient cash runway may lift the stock, while pending Phase 1b readout adds upside potential.
The insider purchase may signal confidence in the company's near‑term prospects, creating modest buying pressure.
AlphAI scores every news story that mentions PMN with an AI model for sentiment and relevance, and aggregates insider trades from ProMIS Neurosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ProMIS Neurosciences (PMN) reported Q3 earnings, highlighting progress in its PMN310 Alzheimer's trial. The company expects cash to last through 2027 and anticipates 12-month trial results in Q1 2027. Interim safety data was encouraging, but efficacy remains unproven. Management also announced new leadership and pipeline expansions.
ProMIS Neurosciences reported Q3 GAAP EPS of -$0.89, exceeding estimates by $0.39. The company had $44.1M in cash as of September 30, 2026, up from $6.1M at the end of 2025, due to a $70.1M private placement. Shares rose 1.72% after hours.
ProMIS Neurosciences reported Q3 2026 financials, with $44.1M cash on hand. Their PRECISE-AD Phase 1b trial for Alzheimer's is on track for 12-month topline data in Q1 2027. PMN310 showed promising interim safety and biomarker results, targeting toxic amyloid-beta oligomers. The company appointed Ivana Rubino as Chief Commercial Officer and expects funds to last through 2027.
ProMIS Neurosciences Inc. (PMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing ● PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month topline data in the first quarter of 2027
Williams Eugene purchased 26,500 shares of ProMIS Neurosciences Inc. (PMN) at $3.43 on 2026-11-04.
Williams Eugene purchased 1,316 shares of ProMIS Neurosciences Inc. (PMN) at $3.99 on 2026-10-30.
Cashman Neil (Chief Scientific Officer) purchased 10,000 shares of ProMIS Neurosciences Inc. (PMN) at $3.86 on 2026-11-02.
Roth Capital kept ProMIS Neurosciences at Buy but cut its price target to $15 from $29, a 48.3% reduction. This implies a 353.2% upside from the Oct 30 close of $3.31.
H.C. Wainwright reiterated a Buy rating and $18.00 price target for ProMIS Neurosciences (PMN). The stock trades at $8.70 with a $78M market cap. Analysts cite potential demand for PMN's amyloid-targeting agent due to lower ARIA risks. PMN reported improved cash position in Q2 2026, with CAD 53.4M in reserves, and appointed Ivana Rubino as Chief Commercial Officer.
H.C. Wainwright reiterated a Buy rating and $18.00 price target for ProMIS Neurosciences (PMN) after the company appointed Ivana Rubino as Chief Commercial Officer. PMN trades at $9.61, with InvestingPro noting its undervaluation and strong cash position. The company reported Q2 cash of CAD 53.4 million and a net loss of CAD 11.7 million, expecting funds to last through 2027.
